<SEC-DOCUMENT>0001437749-21-019373.txt : 20210811
<SEC-HEADER>0001437749-21-019373.hdr.sgml : 20210811
<ACCEPTANCE-DATETIME>20210811083204
ACCESSION NUMBER:		0001437749-21-019373
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210810
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210811
DATE AS OF CHANGE:		20210811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		211162087

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dyai20210809_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dyai="http://www.dyai.com/20210810"><head><!-- Generated by ThunderDome Portal - 8/11/2021 12:23:31 PM -->
	<title>dyai20210809_8k.htm</title>
	<!-- Generated by ThunderDome Portal - 8/11/2021 12:23:31 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20218K" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20218K" name="dei:EntityCentralIndexKey">0001213809</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dyai-20210810.xsd" xlink:type="simple" />
</ix:references>
<ix:resources>
<xbrli:context id="d20218K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001213809</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2021-08-10</xbrli:startDate>
<xbrli:endDate>2021-08-10</xbrli:endDate>
</xbrli:period>
</xbrli:context>


</ix:resources>
</ix:header>
</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin: 0pt; text-align: center;"><b>UNITED STATES</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin: 0pt; text-align: center;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:32.9%;">&#xa0;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:34.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin: 0pt; text-align: center;"><b>FORM <ix:nonNumeric contextRef="d20218K" name="dei:DocumentType"><b>8-K</b></ix:nonNumeric></b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 14pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;; font-size: 14pt;">
			<td style="vertical-align: bottom; width: 32.9%; font-family: &quot;Times New Roman&quot;; font-size: 14pt;">&#xa0;</td>
			<td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 34.1%; font-family: &quot;Times New Roman&quot;; font-size: 14pt;">&#xa0;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;; font-size: 14pt;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CURRENT REPORT</b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Pursuant to Section 13 or 15(d) of the</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&#xa0;</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (date of earliest event reporte<span style="background-color:#ffffff;">d): </span><ix:nonNumeric contextRef="d20218K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><b><b><span style="text-decoration: underline;"><span style="font-family:Times New Roman;font-size:12pt;"><span style="background-color:#ffffff;">August 10, 2021</span></span></span></b></b></ix:nonNumeric></b></div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:32.9%;">&#xa0;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:34.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityRegistrantName"><b>Dyadic International, Inc.</b></ix:nonNumeric></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:32.9%;">&#xa0;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:34.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33%;">&#xa0;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><b>Delaware</b></ix:nonNumeric></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;">(State or other jurisdiction of incorporation or organization)</div>
			</td>
			<td style="vertical-align:top;width:34.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityFileNumber"><b>000-55264</b></ix:nonNumeric></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;">(Commission File Number)</div>
			</td>
			<td style="vertical-align:top;width:33.1%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityTaxIdentificationNumber"><b>45-0486747</b></ix:nonNumeric></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;">(I.R.S. Employer Identification Number)</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:bottom;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressAddressLine1"><b>140 Intracoastal Pointe Drive, Suite 404</b></ix:nonNumeric><br />
			<ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressCityOrTown"><b>Jupiter</b></ix:nonNumeric><b>, <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressStateOrProvince"><b>FL</b></ix:nonNumeric> <ix:nonNumeric contextRef="d20218K" name="dei:EntityAddressPostalZipCode"><b>33477</b></ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:bottom;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 1.1pt;text-align:center;">(Address of principal executive offices and zip code)</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:bottom;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 1.1pt;text-align:center;"><b>(<ix:nonNumeric contextRef="d20218K" name="dei:CityAreaCode"><b>561</b></ix:nonNumeric>) <ix:nonNumeric contextRef="d20218K" name="dei:LocalPhoneNumber"><b>743-8333</b></ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:bottom;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 1.1pt;text-align:center;">(Registrant&#8217;s telephone number, including area code)</div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 2.25pt;text-align:center;"><b>N/A</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 2.25pt;text-align:center;"><b>(Former Name or Former Address, if Changed Since Last Report)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 1.1pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:93.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 1.1pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:93.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 1.1pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:93.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:7%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 1.1pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:middle;width:93.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:right;">Emerging growth company <ix:nonNumeric contextRef="d20218K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Securities registered pursuant to Section 12(b) of the Act</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39.4%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;">Title of each class</div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:19.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 2.25pt;text-align:center;">Trading Symbol(s)</div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:41.2%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 2.25pt;text-align:center;">Name of each exchange on which registered</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:39.4%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;"><ix:nonNumeric contextRef="d20218K" name="dei:Security12bTitle">Common Stock</ix:nonNumeric>, par value $0.001 per share</div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:19.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 2.25pt;text-align:center;"><ix:nonNumeric contextRef="d20218K" name="dei:TradingSymbol">DYAI</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:41.2%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 2.25pt;text-align:center;">The <ix:nonNumeric contextRef="d20218K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric> Stock Market LLC</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#xa0;</b></div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 10pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 10pt; text-indent: -9pt;"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">On August 10, 2021, Dyadic International, Inc. (&#8220;Dyadic&#8221; or the &#8220;Company&#8221;) entered into a binding term sheet (the &#8220;Term Sheet&#8221;) outlining the terms and conditions of an Intellectual Property License Agreement (the &#8220;License Agreement&#8221;) to be entered into within 45 business days. Pursuant to the License Agreement, Dyadic would exclusively license certain patents and patent applications, know-how, trade secrets, proprietary technology, and other intellectual property to Sorrento Therapeutics, Inc. (&#8220;Sorrento" or "Licensee&#8221;), with Sorrento obtaining exclusive rights in&#xa0;North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic&#8217;s C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic&#8217;s lead COVID-19 vaccine candidate. The License Agreement will further set forth that the exclusive license is within the Human Field of Use (as defined in the License Agreement),&#xa0;with a non-exclusive license being granted in the Animal Field of Use (as defined in the License Agreement).&#xa0;&#xa0;Within 30 days after the execution of the License Agreement, Sorrento will pay to Dyadic an up&#8209;front license fee of $10,000,000, of which $5,000,000 will be paid in cash and the remaining $5,000,000 will be paid in shares of Sorrento&#8217;s restricted common stock. Sorrento has agreed to register the shares with the Securities and Exchange Commission ("SEC") pursuant to a registration statement on Form S-3 to be filed by Licensee with the SEC within thirty (30) days after the execution date of the License Agreement and Licensee shall use its best efforts to have such registration statement declared effective by the SEC within ninety (90) days after the execution date of the License Agreement.&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">Dyadic will also receive ongoing royalties for the sale of a Licensed Product, as such term is defined in the Term Sheet, and will receive certain reimbursements not to exceed $4,000,000 for preclinical and clinical development costs incurred by Dyadic in connection with the development of the Licensed Products prior to the effective date of the License Agreement. In addition, Dyadic will receive up to $33,000,000 of non&#8209;refundable, non&#8209;creditable, one-time &#8220;milestone payments&#8221; following the first achievement by Sorrento of certain &#8220;milestone events,&#8221; as described in the Term Sheet.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">The foregoing description of the Term Sheet is only a summary of the material terms thereof, does not purport to be complete and is qualified in its entirety by reference to the full text of the Term Sheet, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 6pt; text-indent: 18pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -12pt; text-indent: 18pt;"><b>Item 8.01 Other Events</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 45pt;">On August 11, 2021, the Company issued a press release regarding the Term Sheet described in Item 1.01. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference, other than th<span style="background-color:#ffffff;">e second through eighth paragraphs&#xa0;of such press release.</span></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -3pt; text-indent: 18pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td colspan="3" style="vertical-align:middle;width:100.5%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 2pt; text-align: left;"><b>Item 9.01 Financial Statements and Exhibits</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:24.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">(d) Exhibits</div>
			</td>
			<td style="vertical-align:bottom;width:0.8%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:75.4%;">&#xa0;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:100.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">The following exhibit is being filed herein:</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.3%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;"><b>Exhibit</b></div>

			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:center;"><span style="text-decoration: underline;"><b>Number</b></span></div>
			</td>
			<td style="vertical-align:bottom;width:0.8%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:75.4%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="text-decoration: underline;"><b>Description</b></span></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:24.3%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:0.8%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:75.4%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 24.3%; text-align: center;">10.1<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></td>
			<td style="vertical-align:bottom;width:0.8%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:75.4%;"><a href="ex_273902.htm" style="-sec-extract:exhibit;">Term Sheet for Intellectual Property License Agreement dated Augus<span style="background-color:#ffffff;">t 10, 202</span>1</a></td>
		</tr>
		<tr>
			<td style="vertical-align:top; width:24.3%; text-align:center">99.1</td>
			<td style="vertical-align:bottom; width:0.8%">&#xa0;</td>
			<td style="vertical-align:bottom; width:75.4%"><a href="ex_274318.htm" style="-sec-extract:exhibit"><span style="background-color:#ffffff;">Press Release Dated August 10, 2021</span></a></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 24.3%; text-align: center;">104</td>
			<td style="vertical-align:bottom;width:0.8%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:75.4%;">Cover page Interactive Data File (embedded within the Inline XBRL document)</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup>&#xa0;In accordance with Item 601(b)(10) of Regulation S-K, certain provisions or terms of the Term Sheet have been redacted.&#xa0;The Company will provide an unredacted copy of the exhibit on a supplemental basis to the SEC or its staff upon request.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURE</b></div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</div>

<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 45pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="background-color:#ffffff;">Date: August 11, 2021</span></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:39.5%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tbody><tr>
			<td colspan="2" style="vertical-align:bottom;width:101.4%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>Dyadic International, Inc.</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:21.5%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:79.9%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:21.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>By:</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:79.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">/s/ Mark A. Emalfarb</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:21.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>Name:</b></div>
			</td>
			<td style="vertical-align:bottom;border-bottom: 1px #000000;;width:79.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Mark A. Emalfarb</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:21.5%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;"><b>Title:</b></div>
			</td>
			<td style="vertical-align:bottom;width:79.9%;">
			<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.25pt;margin-right:0pt;margin-top:0pt;text-align:left;">Chief Executive Officer</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</div>

<div style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex_274318.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html><head>
	<title>ex_274318.htm</title>
	<!-- Generated by ThunderDome Portal - 8/11/2021 12:21:32 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="Page " data-startnum="1" data-suffix=" of 10" data-textalign="right">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.1</b></font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b><i>Certain identified information has been excluded from this exhibit because it is&nbsp;both (i) not material and (ii) would be competitively harmful to the registrant&nbsp;if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark </i></b>&#8220;<b><i>[***]</i></b>&#8221;<b><i>.</i></b></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TERM SHEET FOR INTELLECTUAL PROPERTY LICENSE AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Term Sheet outlines the terms and conditions of an Intellectual Property License Agreement pursuant to which Dyadic International (USA), Inc. (&#8220;<b>Licensor</b>&#8221;) would exclusively license certain patents and patent applications, know-how, trade secrets, and other intellectual property to Sorrento Therapeutics, Inc. (&#8220;<b>Licensee</b>&#8221;). The terms and conditions set forth in this Term Sheet are legally binding upon the parties hereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Licensor:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dyadic International (USA), Inc.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Licensee:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sorrento Therapeutics, Inc.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Licensed IP:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All (i) Licensed Patents, and (ii) all Licensed Know-How.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Licensed Patents</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All (i) patents and applications owned or controlled by Licensor as of the effective date of the License Agreement or at any time during the term of the License Agreement that are necessary or useful to research, develop, make, have made, use, practice, sell, offer for sale, import, export, or otherwise commercialize Licensed Products, including but not limited to the patents and applications listed on <u>Schedule A</u>&nbsp;attached hereto, (ii) any patents issuing or claiming priority from any of the patents and patent applications referenced in clause (i) above, including non-provisionals, continuations in whole or in part, divisionals, reexaminations, and reissues thereof, and (iii) any foreign counterparts of patents and applications referenced in clauses (i) and (ii).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Licensed Know-How</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All data, technology, know-how, trade secrets, inventions, and any other information of any kind whatsoever (including, but not limited to, any pharmacological, biological, chemical, biochemical, manufacturing, business, and financial information), whether patentable or otherwise, copyrights, moral rights, and rights in works of authorship, and all registrations and applications for any of the foregoing, that are owned or controlled by Licensor as of the effective date of the License Agreement or at any time during the term of the License Agreement that are necessary or useful to research, develop, make, have made, use, practice, sell, offer for sale, import, export, or otherwise commercialize Licensed Products, including but not limited to the know-how and technology listed on <u>Schedule A</u>&nbsp;attached hereto.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The term &#8220;Licensed Know-How&#8221;, subject to the limitations below, shall include any cell of <i>Thermothelomyces heterothallica (</i>formerly <i>Myceliophthora thermophila</i>&nbsp;and originally <i>Chrysosporium lucknowense) </i>(&#8220;C1&#8221;) provided by Licensor or otherwise transformed or modified by Licensor, Licensee and/or an authorized third-party to produce a composition of matter suitable for use within the Field of Use.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>License: </b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Except as provided for below, an exclusive, transferable, sublicensable (through multiple tiers) right and license to the Licensed IP as described below. This license grant shall be subject to the terms of that certain Pharma License Agreement, dated December 31, 2015, between Licensor, Danisco US, Inc. and DuPont Experimental Station.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>License Agreement: </b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The parties will use all reasonable efforts to negotiate in good faith and execute the definitive license agreement that will contain terms and conditions consistent with this Term Sheet (the &#8220;<b>License Agreement</b>&#8221;) within forty-five (45) business days of the execution of this Term Sheet.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 1 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Scope of License:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Subject to the terms and conditions of the License Agreement, an exclusive license under the Licensed IP to research, develop, make, have made, use, practice, sell, offer for sale, import, export, and otherwise commercialize the Licensed Products within the Human Field of Use in the Territory during the Term and a non-exclusive license within the Animal Field of Use in the Territory during the Term. Notwithstanding the foregoing and for the avoidance of doubt: (i) within the Territory, Licensor shall have a royalty-free, co-exclusive right to practice and use the Licensed IP, directly or through a third party, within the Field of Use solely for research and development purposes and (ii) Licensor shall retain all other rights with respect to the Licensed IP including, without limitation, with respect to the Field of Use outside of the Territory. Nothing in this Term Sheet or the License Agreement shall be deemed, directly or indirectly, to interfere with Licensor&#8217;s right and license to practice or use the Licensed IP outside of the Field of Use, including, without limitation, the development of capabilities that may be useful to make, have made, use, sell, offer to sell, export or import Licensed Products within the Field of Use and/or within or without the Territory.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Field of Use:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any and all fields of use for or in respect of the diagnosis, prophylaxis and/or treatment of any disease or condition in a human or animal by targeting any virus or subpart thereof of a coronavirus, including, without limitation, SARS-CoV-2. With respect to the foregoing, applications directed exclusively to animals other than humans shall be known as the &#8220;Animal Field of Use&#8221;&nbsp;and with respect to humans, the &#8220;Human Field of Use.&#8221;&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Territory:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Worldwide, except the Excluded Countries and Continents as set forth below.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Excluded Countries: Israel; South Korea; Singapore; Thailand; Indonesia; Malaysia; Cambodia; Myanmar; Philippines; Vietnam; Laos; and Cuba.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Excluded Continents: Africa (including Madagascar); and Indian Sub-Continent, specifically India, Pakistan, Bangladesh, Nepal, Sri Lanka, Bhutan, the Maldives, and Mauritius.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Licensed Product(s):</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Any product, process, service, method, composition, apparatus, or device the research, development, manufacture, use, sale, offer for sale, importation, exportation, lease disposition, or other commercialization of which would infringe, misappropriate, or otherwise violate any Licensed IP (including pending applications) but for the license granted in the License Agreement<b>&nbsp;</b>or that otherwise arose out of, embodies, is enabled by, or is covered by the Licensed IP. For the avoidance of doubt, the term &#8220;Licensed Product&#8221;&nbsp;shall include, without limitation, any such product, process, service, method, composition, apparatus, or device made in C1 or otherwise arising out of or relating to any Licensed Know-How transmitted to Licensee.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Term of the License:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The expiration or abandonment of the Licensed IP or for so long as Licensee is developing or selling a Licensed Product (the &#8220;<b>Term</b>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 2 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Upfront Fee:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee would pay to Licensor an up-front license fee of ten million dollars ($10,000,000) (the &#8220;<b>Upfront Fee</b>&#8221;), of which Five Million Dollars ($5,000,000) will be paid in cash within thirty (30) days after the execution of the License Agreement, and the remaining Five Million Dollars ($5,000,000) will be paid in shares of restricted Licensee common stock, with the number of shares to be issued in respect thereof to be determined based on the volume weighted average price of the shares of Licensee common stock traded on The NASDAQ Stock Market LLC (&#8220;Nasdaq&#8221;) for the eleven consecutive trading days ending five trading days prior to the execution date of the License Agreement; provided, however, that for purposes of rules of NASDAQ, the total number of shares of Licensee common stock issuable as payment for a portion of the Upfront Fee shall not exceed 19.99% of the outstanding shares of Licensee common stock as of immediately prior to the execution of the License Agreement. The restricted shares shall be registered with the Securities and Exchange Commission ("SEC") pursuant to a registration statement on Form S-3 to be filed by Licensee with the SEC within thirty (30) days after the execution date of the License Agreement and Licensee shall use its best efforts to have such registration statement declared effective by the SEC within ninety (90) days after the execution date of the License Agreement, subject to Licensor promptly providing to Licensee all information regarding Licensor that is required to be included in the resale registration statement. The License Agreement shall include other reasonable and customary terms associated with such resale registration statement.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Royalties:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Running Royalties: [***]%&nbsp;of Net Sales received in consideration for the sale of a Licensed Product which comprises any vaccine containing the sequence of a SARS-CoV-2 antigen, including without limitation, the product known as DYAI-100 or variants thereof, and [***]% of Net Sales for all other Licensed Products.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement shall contain a combination product clause.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The running royalty may be reduced by Licensee on account of payments made to third parties under a bona fide arm&#8217;s length agreement arising out of or relating to intellectual property licensed from such third party where such intellectual property is (a) necessary to sell Licensed Products in the Territory and in the applicable Field of Use and (b) such requirement arises exclusively from the use of the Licensed IP (&#8220;Blocking Third Party IP&#8221;). In no event shall the running royalty rate be reduced by more than [***]&nbsp;%&nbsp;on account of this provision. The License Agreement shall contain provisions relating to such Blocking Third Party IP pursuant to which Licensor shall have the right and authority to negotiate a license or otherwise obtain rights or indemnify Licensee from any liability for such Blocking Third Party IP in lieu of any royalty reduction.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The royalty term expires, on a Licensed Product-by-Licensed Product and country-by-country basis, on the later of (i) 12.5 years from first commercial sale of the applicable Licensed Product in such country, or (ii) the last to expire valid claim of an issued patent comprising the Licensed Patents that would be infringed by the sale or approved use of a Licensed Product in such country.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>&#8220;Net Sales</b>&#8221;&nbsp;shall mean, in accordance with generally accepted accounting principles for financial reporting in the United States, consistently applied, the total gross amount invoiced by Licensee or a Permitted Sublicensee from an arms-length final commercial sale by Licensee or Permitted Sublicensee to a customer of a Licensed Product less the following discounts:</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any shipping, freight, postage, transportation, storage, and insurance costs and reasonable expenses directly relating thereto;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 3 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;allowances, discounts or credits given because of rejected or returned Licensed Products;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sales, excise and similar tariffs and taxes, including customs duties;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;customary trade, quantity and cash discounts actually allowed and taken, including rebates granted; and</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;customary and normal fees payable to purchasers, sales agents, distributors, resellers, group purchasing organizations, government agencies, and like entities.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Milestones: </b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee would pay Licensor the following non-refundable, non-creditable, one-time milestone payments following the first achievement by Licensee of each milestone event listed below with respect to a Vaccine Product or Therapeutic Product (as defined below):</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>&#8220;Vaccine Product</b>&#8221;&nbsp;shall mean any Licensed Product that comprises a vaccine and is suitable for use in the Field of Use.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>&#8220;Therapeutic Product</b>&#8221;&nbsp;shall mean any Licensed Product that is not a vaccine and is suitable for use in the Field of Use.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Milestone Payments</u></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon dosing of 1<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup>&nbsp;patient in Phase 2 clinical trial in the US, Europe, Japan or China for the first Vaccine Product</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon dosing of 1<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup>&nbsp;patient in Phase 3 clinical trial in the US, Europe, Japan or China for the first Vaccine Product</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon dosing of 1<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup>&nbsp;patient in Phase 2 clinical trial in the US, EU, Japan or China for the first Therapeutic Product</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon dosing of 1<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup>&nbsp;patient in Phase 3 clinical trial in the US, EU, Japan or China for the first Therapeutic Product</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 45pt; text-indent: -27pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in the US for the first Vaccine Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in China or Japan for the first Vaccine Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in Europe for the first Vaccine Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in the US for the first Therapeutic Product</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 4 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in China or Japan for the first Therapeutic Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in Europe for the first Therapeutic Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in the US for the first animal Vaccine Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in China or Japan for the first animal Vaccine Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in Europe for the first animal Vaccine Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in the US for the first animal Therapeutic Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in China or Japan for the first animal Therapeutic Product</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;text-indent:-18pt;">&#9679;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$[***] upon first marketing approval in Europe for the first animal Therapeutic Product</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Patent Prosecution:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensor would be responsible for filing, prosecution and maintenance (collectively, &#8220;<b>Prosecution</b>&#8221;) of all Licensed Patents at Licensee&#8217;s expense, <i>provided that</i>&nbsp;Licensor would keep Licensee informed as to the status of the Prosecution, provide Licensee copies of all material correspondence to and from the patent offices and provide Licensee with opportunities to comment and reasonably accommodate those comments.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement will have customary provisions relating to Prosecution.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Enforcement:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensor would have first right of enforcement, but if Licensor declines to enforce the Licensed IP in the Territory and in the Field of Use, Licensee would have the right, subject to additional customary limits in the License Agreement, to enforce the Licensed IP.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement will have customary provisions relating to enforcement.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Development &amp; Commercialization:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall use commercially reasonable efforts to and assume full responsibility for all future development and commercialization of the Licensed Product(s) at its own expense.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensor shall have the option, with respect to Vaccine Products, to convert the exclusive license granted under the License Agreement to a non-exclusive license if the Licensee fails to initiate a Phase 2 trial of a Vaccine Product by [***], such period which may be extended by mutual agreement of the parties; furthermore, any non-exclusive rights relating to Vaccine Products shall terminate automatically if such Phase 2 has not been initiated by [***].</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 5 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensor shall have the option, with respect to Therapeutic Products, to convert the exclusive license granted under the License Agreement to a non-exclusive license if the Licensee fails to initiate a Phase 1 trial of a Therapeutic Product by [***], such period which may be extended by mutual agreement of the parties; furthermore, any non-exclusive rights relating to Therapeutic Products shall terminate automatically if such Phase 1 has not been initiated by [***].</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensor shall have the option, with respect to either Human Vaccine Products and/or Therapeutic Products, to convert the exclusive license granted under the License Agreement to a non-exclusive license if the Licensee fails to initiate a Phase 1 trial of a Licensed Product within one (1) year of the World Health Organization and/or the Centers for Disease Control declaring a &#8220;pandemic&#8221;&nbsp;with respect to a coronavirus other than SAR-CoV-2 and its variants of concern in the Territory.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Additionally, Licensee shall reimburse Licensor all preclinical and clinical development costs that were incurred by Licensee prior to the effective date of the License Agreement in connection with the development of Licensed Products, <i>provided that</i>&nbsp;such reimbursement shall not exceed four million dollars ($4,000,000). Any reimbursement would be paid within thirty (30) days of receipt of invoice and supporting documentation.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Transfer and Sublicense Rights</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall have sublicense rights as is reasonably required to, on its own behalf, exercise the rights provided for herein. All such sublicense rights shall be made to an entity of equal or superior capabilities as Licensee and shall be subject to the prior written approval of the Licensor, such consent not to be unreasonably withheld, delayed or conditioned (a "Permitted Sublicensee&#8221;&nbsp;and a &#8220;Permitted Sublicense&#8221;). Without limiting the generality of the foregoing, it shall be unreasonable for Licensor to withhold approval of a potential sublicensee if such potential sublicensee has capabilities commensurate with or greater than Licensee&#8217;s capabilities. All Permitted Sublicenses shall be pursuant to a written agreement by which the Permitted Licensee, whose performance shall be guaranteed by Licensee, shall covenant to abide by all of the terms of the License Agreement and such Permitted Sublicense shall name Licensor as a third-party beneficiary with a right of enforcement. The rights provided for herein shall not extend to either the transfer of all or substantially all of the rights to any Licensed Product, either directly or via sublicense, to a third party where such transfer or sublicense permits such third party to control the development, sale, offer for sale, manufacturing, or other commercial aspects of the Licensed Product. In the event a Permitted Sublicense is executed, Licensor shall be entitled to [***] of any upfront payment made to Licensee on account of such Permitted Sublicense.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee shall assume full responsibility for the clinical and commercial manufacture and supply of the Licensed Product at its own expense.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Chemistry, Manufacturing and Control (</b>&#8220;<b>CMC</b>&#8221;<b>) Materials:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensor will provide Licensee with drug material related to the DYAI-100 and manufactured under cGMP conditions, whether or not currently qualified, which is currently in its or its affiliates&#8217;&nbsp;possession (the License Agreement will include an appendix listing the exact amount and description of such materials). Upon transfer of the drug material provided for herein, Licensor shall promptly provide Licensee with the release criteria and other relevant information from the contract manufacturer who produced the drug material. Such release shall be &#8220;as is&#8221;&nbsp;and without any warranty or representation.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 6 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Additional Provisions</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement will include additional provisions providing, <i>inter alia</i>, audit, inspection and books and records rights, a right of reference by Licensor for regulatory filings relating to any Licensed Product on its own behalf and on behalf of its other licensees, reporting obligations, regulatory review and interaction rights and pharmacovigilance.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Technology Transfer:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement will include mutually agreed provisions governing (a) the transfer of Licensed IP to Licensee necessary or useful to enable Licensee to fulfill its development and commercialization obligations under the License Agreement, including necessary or reasonably useful biological materials, reagents and manufacturing processes, and (b) the manufacture of clinical supply of the Licensed Products. If requested by Licensee, Licensor, or its collaborator(s) shall provide reasonable assistance to Licensee, such assistance to be reimbursed by Licensee at an hourly rate, such hourly rate not to exceed &#8364;[***] per FTE as calculated on an annual basis.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Licensee agrees that, as partial consideration of access to the Licensed Know-How and the lease of C1 strains and related tools, that any and all inventions, discoveries, improvements, extensions of the Licensed IP, arising out of or relating to the Licensed Know-How (&#8220;New IP&#8221;), whether patentable or not, shall be owned by Licensor and, pursuant to the terms of the License Agreement, licensed back to Licensee. For the sum of One Dollar ($1) Licensee, on its own behalf and on behalf of any third party it controls, hereby assigns its entire right, title and interest in and to such New IP. The License Agreement shall have appropriate provisions relating to disclosure, filing, prosecution, and enforcement of any potentially patentable inventions covered by the foregoing provision.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Miscellaneous:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The License Agreement would include other customary terms and conditions, including, without limitation, representations, warranties, covenants and indemnities by each party and customary confidentiality, termination and dispute resolution provisions.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Nature of Term Sheet:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">It is the intention of the parties referenced in this Term Sheet that this Term Sheet be a legally binding obligation of such parties.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Confidentiality:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Neither party will disclose the terms of this Term Sheet to any person or entity other than such party&#8217;s officers, members of the Board of Directors, accountants, attorneys and other advisors who are bound to such party by a duty of confidentiality, in any case without the written consent of the other party.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Governing Law and Disputes: </b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Term Sheet and the License Agreement will be governed by Delaware law, without regard to conflicts of law principles.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Expenses:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Each party will bear its own expenses incurred in the drafting and negotiation of this Term Sheet and the License Agreement.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 7 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exclusivity:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the period commencing on the date on which both parties have executed this Term Sheet (the &#8220;Effective Date&#8221;) and ending at 5:00 p.m. San Diego, California local time on the date that is Forty Five (45) days from the Effective Date (the &#8220;Exclusivity Period&#8221;), Licensor (including its directors, officers, managers, employees and professional advisors) will negotiate exclusively and in good faith with Licensee with respect to entering into the License Agreement and the other matters contemplated by this Term Sheet. During the Exclusivity Period, Licensor (including its directors, officers, managers, employees and professional advisors) will not, directly or indirectly, solicit, initiate, seek, entertain, knowingly encourage, knowingly facilitate or support any inquiry, proposal or offer from, furnish any information to, or participate in any discussions or negotiations with, any person or entity other than Licensee and its representatives with respect to any sale or other disposition of any equity securities of Licensor, or any merger, consolidation, business combination or similar transaction, any sale, license, lease or other disposition of all or substantially all of the assets of Licensor or any assets related to the Licensed Products (a &#8220;Competing Proposal&#8221;), or enter into any agreement with any such other person or entity concerning such a transaction. Licensor further covenants and agrees to terminate any such discussions or negotiations in respect of a Competing Proposal in progress as of the Effective Date. If Licensor (including any of its directors, officers, managers, employees or professional advisors) receives an offer or expression of interest to make an offer for a Competing Proposal from a third party, Licensor will promptly (but in any event within 24 hours) notify Licensee in writing of the terms and conditions of such offer and the identity of the person or entity making such offer. Nothing in this provision is intended to prevent or delay Licensor from undertaking any ordinary course activities unrelated to the out-licensing of Licensed IP in the Field of Use, including, without limitation, consummating the sale of equity securities.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Expiration:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The proposals under this Term Sheet will expire unless this Term Sheet is accepted by Dyadic International (USA), Inc. prior to 5:00&nbsp;p.m. Pacific Time on August 12, 2021 (the &#8220;<b>Term Sheet Deadline</b>&#8221;). In the event this Term Sheet is executed by the Term Sheet Deadline, this Term Sheet shall terminate upon the earliest to occur of: (i) execution of the License Agreement by each of the parties or (ii) mutual written agreement of the parties.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:74.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:26.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Publicity:</b></p>
			</td>
			<td style="vertical-align:top;width:74.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Following the execution of this Term Sheet, each party may issue a press release in substantially the form presented to and approved by the other Party concurrently with the execution of the applicable agreement, with such approval not to be unreasonably withheld, conditioned or delayed. Notwithstanding anything herein to the contrary in this Term Sheet, both parties shall be free to make any disclosure if required to (i) comply with the requirements of any applicable laws (in which case such party shall notify the other party promptly and shall use commercially reasonable efforts to provide the other party with a copy of the contemplated disclosure prior to submission or release, as the case may be); (ii) enforce any right or remedy of any right or remedy relating to this Term Sheet or (iii) as required to any potential partner, financing source, advisor or similar entity provided that such third party execute a confidentiality agreement at least as restrictive as the confidentiality provided for herein. Without limiting the foregoing, each party shall be permitted to publicly disclose this Term Sheet, and/or the terms contained herein or therein to the extent required by applicable law or regulation.</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:101.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:101.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:center;margin:0pt 0pt 0pt 108pt;text-indent:-108pt;"><b>[Remainder of Page Intentionally Left Blank]</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 8 of 10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;margin:0pt;text-indent:5pt;"><b>This</b> <b>Term Sheet For Intellectual Property License Agreement</b> is accepted and agreed to by Sorrento Therapeutics, Inc. and Dyadic International (USA), Inc. as of the date(s) set forth below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 0pt; margin-right: auto;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>SORRENTO THERAPEUTICS, INC.</b></td>
			<td style="vertical-align: top; width: 50.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DYADIC INTERNATIONAL (USA), INC.</b></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By: /Henry Ji/</p>
			</td>
			<td style="vertical-align: top; width: 50.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By: /Mark Emalfarb/</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Henry Ji, Ph.D.</p>
			</td>
			<td style="vertical-align: top; width: 50.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name: Mark Emalfarb</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title: Chairman, President and CEO</p>
			</td>
			<td style="vertical-align: top; width: 50.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title: CEO</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50.4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: August 10, 2021</p>
			</td>
			<td style="vertical-align: top; width: 50.8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: August 10, 2021</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 10%; border: thin solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Sorrento</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Legal </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Approved</b></p>
			</td>
			<td style="width: 90%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" data-number="9" data-prefix="Page " data-suffix=" of 10" style="text-align: right; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 9 of 10</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SCHEDULE A</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Licensed IP</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<table cellpadding="1pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt; border: 1px solid black;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 26.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 77.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">[***]</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 26.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">[***]</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 77.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">[***]</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 26.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">[***]</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 77.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">[***]</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 26.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">[***]</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 77.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">[***]</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 144pt;text-indent:-144pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="Page " data-suffix=" of 10" style="text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">Page 10 of 10</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex_273902.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_273902.htm</title>
	<!-- Generated by ThunderDome Portal - 8/11/2021 12:31:18 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div><img alt="logo01.jpg" src="logo01.jpg"></div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: center;"><b>DYADIC AND SORRENTO ANNOUNCE BINDING TERM SHEET TO LICENSE DYADIC</b>&#8217;<b>S LEAD COVID-19 VACCINE CANDIDATE </b>&#8220;<b>DYAI-100</b>&#8221;<b> AND C1 TECHNOLOGY FOR PROTEIN-BASED CORONAVIRUS VACCINES AND THERAPEUTICS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 48pt; padding-left: 9pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;"><i>Sorrento to obtain&nbsp;exclusive rights in&nbsp;North and South America, Europe,&nbsp;major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic</i>&#8217;<i>s C1 technology for the development and commercialization&nbsp;of vaccines, therapeutics antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic</i>&#8217;<i>s lead COVID-19 vaccine candidate </i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 48pt; padding-left: 9pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;"><i>Exclusivity is subject to Sorrento</i>&#8217;<i>s timely achievement of certain development milestones</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 48pt; padding-left: 9pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;"><i>Expands Sorrento</i>&#8217;<i>s extensive COVID-19 programs and corporate mission to develop novel vaccines and therapeutic treatments for unmet needs</i></p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width: 48pt; padding-left: 9pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -36pt;"><i>Consideration includes a $10 million up-front payment ($5 million in cash and $5 million in Sorrento stock), reimbursement of certain DYAI-100 R&amp;D expenses, with potential for multiple future development milestones and royalty payments </i></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;"><b>JUPITER, FL / August 11, 2021&nbsp;</b>Dyadic International, Inc. (&#8220;Dyadic&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221;) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve access to biologic vaccines and drugs at flexible commercial scales, and Sorrento Therapeutics, Inc. ("Sorrento") (NASDAQ: SRNE), a clinical stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, today announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses,&nbsp;, including Dyadic&#8217;s lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform. The final terms of the license will be set forth in a definitive agreement to be entered into between the parties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Sorrento&#8217;s Chairman and CEO, Dr. Henry Ji, commented, &#8220;We look forward to continuing our collaboration with Dyadic, which began last year, initially with a goal of developing and commercializing a protein-based COVID-19 vaccine that can be rapidly manufactured in large quantities in our existing cGMP facilities, and stored and transported at room temperature, in order to increase access and affordability to underserved populations globally.&#8221;&nbsp; Dr Ji. continued, &#8220;Over the past six months we have carried out several promising preclinical animal trials using the C1 produced RBD antigen in Dyadic&#8217;s lead COVID-19 vaccine candidate, DYAI-100.&nbsp; Our goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across our current and future coronavirus programs&#8221;.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Mark Emalfarb, Dyadic&#8217;s President and Chief Executive Officer noted, &#8220;We are delighted to have executed a binding term-sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19. This marks a significant milestone in our corporate development efforts as we expect the license agreement we will enter into to enable us to monetize our internal COVID-19 development efforts with a partner that has the resources and expertise to advance vaccines, therapeutics, and diagnostics both clinically and commercially&#8221;.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#8220;The license agreement, when executed, contemplates an up-front payment of $10 million in cash and stock, up to $4 million in reimbursements for preclinical and clinical development costs incurred by Dyadic for the development and advancement of our proprietary DYAI-100 vaccine, up to $33 million in milestone payments and ongoing royalties following commercialization. All future development costs related to this license will be incurred by Sorrento&#8221;, concluded Mr. Emalfarb.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Mr. Michael Tarnok, Dyadic&#8217;s Board Chairman noted, &#8220;This is a significant event for Dyadic and humankind globally, having achieved our goal of creating a pathway that potentially addresses the COVID-19 vaccine production gap for mass scale immunizations and treatments across the globe, quickly and efficiently. The Sorrento license will cover all other territories not already covered by Dyadic&#8217;s existing COVID-19 agreements with Medytox, Syngene and the Rubic Consortium&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>About Sorrento Therapeutics Inc. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (&#8220;G-MAB&#8482; library&#8221;), clinical stage immuno-cellular therapies (&#8220;CAR-T&#8221;, &#8220;DAR-T&#8482;&#8221;), antibody-drug conjugates (&#8220;ADCs&#8221;), and clinical stage oncolytic virus (&#8220;Seprehvir&#8482;&#8221;). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD&#8482;, COVI-AMG&#8482;, COVISHIELD&#8482;, Gene-MAb&#8482;, COVI-MSC&#8482; and COVIDROPS&#8482;; and diagnostic test solutions, including COVITRACK&#8482;, COVI-STIX&#8482; and COVITRACE&#8482;.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (&#8220;RTX&#8221;), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA&#8482;), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido&#174; (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido&#174; was approved by the FDA on February 28, 2018.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">For more information visit www.sorrentotherapeutics.com.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt;"><b>About Dyadic International, Inc.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Dyadic International, Inc. is a global biotechnology company that is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus&nbsp;<i>Thermothelomyces heterothallica (formerly Myceliophthora thermophila)</i>, named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing, which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Please visit Dyadic's website at&nbsp;http://www.dyadic.com&nbsp;for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 6pt;"><b>Safe Harbor Regarding Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding Dyadic's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Forward-looking statements generally can be identified by use of the words &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;pursue,&#8221; or &#8220;continue&#8221; and other similar terms or variations of them or similar terminology. However, not all forward-looking statements contain these words. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">(1) the expected entry into a definitive license agreement with Sorrento, (2) the development and commercialization of COVID-19 vaccines, including DYAI-100, and therapeutic antibodies, protein therapeutics and diagnostics for coronaviruses; (3) the properties of DYAI-100, including its induction of high-titer neutralization activity against SARS-CoV-2 and its variants of concern, (4)&nbsp; the capability to manufacture protein-based vaccines in large quantities; (5) the resources and expertise of Dyadic and its partners in developing and commercializing vaccines, therapeutics and diagnostics; (6) the expectation that such vaccines would be effective against SARS-CoV-2 and its variants of concern; (7) general economic, political and market conditions; (8) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (9) our ability to implement and successfully carry out Dyadic&#8217;s and third parties&#8217; research and development efforts; (10)&nbsp;the pharmaceutical and biotech industry, governmental regulatory and other agencies&#8217; willingness to adopt, utilize and approve the use of the C1 gene expression platform;&nbsp;and (11) other factors described in the Company's most recent filings with the SEC. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this press release are made only as of the date hereof, and Dyadic does not intend, and except as required by law assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;), as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and www.dyadic.com.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Contacts:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Sorrento Therapeutics Inc. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Alexis Nahama,&nbsp;DVM</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">SVP Corporate Development</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Email: mediarelations@sorrentotherapeutics.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Sorrento&#174; and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">G-MAB&#8482;, DAR-T&#8482;, SOFUSA&#8482;, COVIGUARD&#8482;, COVI-AMG&#8482;, COVISHIELD&#8482;, Gene-MAb&#8482;, COVIDROPS&#8482;, COVI-MSC&#8482;, COVITRACK&#8482;, COVITRACE&#8482; and COVISTIX&#8482; are trademarks of Sorrento Therapeutics, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">SEMDEXA&#8482; is a trademark of Semnur Pharmaceuticals, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">ZTlido&#174; is a registered trademark owned by Scilex Pharmaceuticals Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">All other trademarks are the property of their respective owners.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b>Dyadic International, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Ping W. Rawson</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Chief Financial Officer</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Phone: (561) 743-8333</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Email: prawson@dyadic.com</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>dyai-20210810.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/11/2021 12:23:34 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dyai="http://www.dyai.com/20210810" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.dyai.com/20210810">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20210810_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20210810_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dyai-20210810_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.dyai.com/20210810/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="dyai_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>dyai-20210810_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/11/2021 12:23:34 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.dyai.com/20210810/role/statement-document-and-entity-information" xlink:href="dyai-20210810.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.dyai.com/20210810/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>dyai-20210810_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/11/2021 12:23:34 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>dyai-20210810_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/11/2021 12:23:34 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.dyai.com/20210810/role/statement-document-and-entity-information" xlink:href="dyai-20210810.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.dyai.com/20210810/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>logo01.jpg
<TEXT>
begin 644 logo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 &\# 2(  A$! Q$!_\0
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M_P"@K8?]\O\ X5[-IG_(+M/^N*?^@BK5:*E&QSO&UD]SP_\ X4IK7_05L/\
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I9_R"[3_KBG_H(JY4<4:0Q)&@PB*%4>@%25:V,&[L****!!1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>dyai20210809_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="dyai-20210810.xsd" xlink:type="simple"/>
    <context id="d20218K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213809</identifier>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20218K">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20218K">0001213809</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20218K">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20218K">2021-08-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20218K">Dyadic International, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20218K">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20218K">000-55264</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20218K">45-0486747</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20218K">140 Intracoastal Pointe Drive, Suite 404</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20218K">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20218K">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20218K">33477</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20218K">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20218K">743-8333</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20218K">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20218K">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20218K">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20218K">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="d20218K">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="d20218K">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20218K">DYAI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20218K">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140461289442856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">Dyadic International, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Aug. 10,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">000-55264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">45-0486747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">140 Intracoastal Pointe Drive, Suite 404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">33477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">743-8333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DYAI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001213809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M 40+4]Q!4!(W!   91   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R5
MF%USXC84AJ^WOT+#53L38LN8C^P09DA(NG2S61IH=]I.+X0M0!-;<B5Y"?^^
M1P9L.C7'Y":VC/3JD73T'BG#K=*O9L.Y)6]I(LUM:V-M]M'S3+3A*3/7*N,2
M?EDIG3(+1;WV3*8YBXM&:>(%OM_S4B9D:S0LOLWT:*ARFPC)9YJ8/$V9WMWQ
M1&UO6[1U_/ BUAOK/GBC8<;6?,[M;]E,0\DK56*1<FF$DD3SU6UK3#_>!:%K
M4-3X7?"M.7DG;BA+I5Y=81K?MGQ'Q!,>62?!X/&=W_,D<4K \<]!M%7VZ1J>
MOA_5'XO!PV"6S/![E7P3L=W<M@8M$O,5RQ/[HK:?^&% 7:<7J<04?\EV7S?L
MMDB4&ZO20V,@2(7</]G;82).&] S#8)#@Z#@WG=44$Z89:.A5ENB76U0<R_%
M4(O6 ">D6Y6YU?"K@'9V-%%1#I-LR5C&Y$%:87=D*O>K#;,V]"QTXJIZT4'P
M;B\8G!$<Y^MK0OTK$O@!_6]S#]A*P* $# J]3A/@"17YZPEJD:GEJ?D;Z:-3
M]M$I^@C/]+$?]Q5YX6MAK&;0VS-+>=W@<:')CL4B E3+M2Q067(%Q>@:H0Q+
MRA 7/\S$%5GLLEHXO/V@_1FAZ)84W0LI9EP+Y8(F)A!ZM4"XU#%4?OCPH2%8
M>B5<[Z*%A!E7.E.Z6((K,K? 1Y0F]RJ75N_@&=?RXNJ3!P2Q7R+V+T)\% DG
MSWFZY+J.!!?Q?;_=[0:]$ $:E$"#BX 6[(U,8UA9L1+1?IN=Q\,EPV[;#P>]
M?MA'^&Y*OIN+^,9QK+DQY0LI/."KK%U(7)*&OMNCFD6*&<L2,E,"MBR9:,@0
M$"ZY@$+H8[-+_<I@_??QWSN/A6!<J&V]O^)ZO^09X&F,[<3\Z?O8RITRT^J[
MD%'MY#:(/CYA;)7OT^!];#-5K-6?(CN[?QLD.YVPCX4DK1(&Q8V^6,,Q'(/.
MH^ "W1[F=[3*"10W]2<5N?C=*(FY28-(/^RT!YU.!R.J\@/%7?V;%M9R"1.3
MIKD\6(FII<*%5BPQ'$.JL@+%C7NN$A$)*^2:?('XUH(EM3RX2B-/E0(H;M\S
MS=L13 ^'#5:<;19<QER3KZO5F?7#]1K)JEQ <>?^']G4F!S(&@%QV4; *AG0
MR[+!0\KUVBWHSR!A-R[:,B9WM6RX8A-;4#E]@#OS0EC(Z6I%:/#C\B<RYU$.
M>Z&6J4')[1W(OW.KHE<,K3+Z /?DA8:#*<S6?)<N56WP-PA,_AA/,9*3XSSN
MP<=9(0]OT8;)-3][U&X0>A[/)^-?,:;*S0/<C,<0ZG$1[H\)6]>RX *-,53Y
M>8!;\3&^[[D[GR1P3(GY&_G,ZZ,(UX)3(@UH9^#?U*%Y)Y=&=P'_PMR&,B3A
M*U#SK_O@SGI_I]T7K,J*>^126;B5%J\;SL 67 7X?:64/1;<U;3\S\+H7U!+
M P04    "  !1 M3GZ ;\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=5VUK
MVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-
MH<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=5
M6R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0G
MCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$
M[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,
M/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!
M6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@
M?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\
M@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T
M7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIU
MTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'
M!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=
M/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@
M/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&
MD3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?
M)=-[*CG_5U/\!%!+ P04    "  !1 M3EXJ[',     3 @  "P   %]R96QS
M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0
M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#
ML%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S
M##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H
M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  %$"U,ZJJ+G0 $  #P"   /
M    >&PO=V]R:V)O;VLN>&ULC5%=:\,P#/PKQC]@2<M66&D&8]U'86QE'7UW
M8J41M:U@J^W67S\E(:RPESW).HG3W7EQHK@OB?;JR[N0"MTPM_,L2U4#WJ0K
M:B'(I*;H#4L;=UEJ(QB;&@#V+IOF^2SS!H.^6XQ<ZYA=-L10,5(0L .V"*?T
M.^]:=<2$)3KD[T+W;P=:>0SH\0RVT+E6J:'3"T4\4V#C-E4DYPH]&09;B(S5
M'WC3B?PT9>H1-N6'$2&%GN5"6&-,W&_T_$8T'D&6A^[ ](2.(2X-PW.D0XMA
MU]&(B^S"1I_#6(<0Y_$_,5)=8P5+J@X> @\Y1G"=P) :;)-6P7@H]+BB[H-5
MCX$E)+4* Y7L=D[E],H.KEGD7F08YRB#N+*#\%&MA1H#V#<YD 27Y*IU5%WI
M>:;7-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @  40+4R0>FZ*M
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  !1 M3LWY1XNT    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  !
M1 M3F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    (  %$"U/<05 2-P0  &40   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  !
M1 M3GZ ;\+$"  #B#   #0              @ %Y#   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    (  %$"U.7BKL<P    !,"   +              "  54/
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  %$"U,ZJJ+G0 $  #P"   /
M          "  3X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  !1 M3
M)!Z;HJT   #X 0  &@              @ &K$0  >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  !1 M399!YDAD!  #/ P  $P
M        @ &0$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"
(  #:$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="dyai20210809_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.dyai.com/20210810/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="dyai20210809_8k.htm">dyai20210809_8k.htm</File>
    <File>dyai-20210810.xsd</File>
    <File>dyai-20210810_def.xml</File>
    <File>dyai-20210810_lab.xml</File>
    <File>dyai-20210810_pre.xml</File>
    <File>ex_273902.htm</File>
    <File>ex_274318.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dyai20210809_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "dyai-20210810_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dyai20210809_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dyai-20210810_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dyai-20210810_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dyai-20210810.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "dyai",
   "nsuri": "http://www.dyai.com/20210810",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210809_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.dyai.com/20210810/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "dyai20210809_8k.htm",
      "contextRef": "d20218K",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document, Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document, Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity, Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity, Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity, Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity, Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity, Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity, Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity, Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity, Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity, Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.dyai.com/20210810/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001437749-21-019373-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-21-019373-xbrl.zip
M4$L#!!0    (  %$"U-8-A=-;P,  "@.   1    9'EA:2TR,#(Q,#@Q,"YX
M<V3-5U%OTS 0?D?B/YB\IVY:AM9J'4(,4*4Q$!L2;\BUW=8BL8/M;.N_Y^S$
M:;VE6UHDQ%,=^_M\WYW/Y^O9V_LB1[=<&Z'D+,D&PP1Q2143<C5+OE^G[Z[?
MS^<),I9(1G(E^2R1*GE[_O+%V:LT_<0EU\1RAA8;=+.N)./Z0A4<?57:DARE
MZ!1G&1X-1QG*1M/1>#I^C;Y^3E/'OS=L:NB:%P2!"&FF]PN=BUFRMK:<8GQW
M=S=P,P.E5[##<(R%=#(H3P+>L A]-P[8#/_X?'GM]V[!N9"_NN#99#+!?C5
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M3=R+1U?O+Y'\_U/%*_\!4$L#!!0    (  %$"U,"9BO<= 0  'XM   5
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M<\F4I+0I0Q)1AC]FZ,J2]3N5,[ T@>=6R$FU7R6-^GZKO1&3[J-EU:QI<HS
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M \.R=M'MU8\DY46(Y]=%IU@..]OG?_"E#D/LG!TU65-[\TD/;R8%AT'%>.<
M_?K9@#DN<+P[PL7+AL0NX9#>8?RBL*".63T8#"]-X/T99Q,(2.,+4"_4!:CB
MQT&=NZX#R9P!.>L-1T9ZIJ7PS,U.S]+$1, /D1SPU_!V_P-02P,$%     @
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M+":R$$.E4J&NHJ2*X=>1R::BG.@"ON+U#U4DJT()^%,7#', [42LZPV19B7
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M%9'10T1]?#>Z@'7A[QEC*,@R@:%J\POV%),( F'CO-O'I!3,BZ0>2;I8'()
MF@Z!(AX/>F)[:_ 4E !57F+$J":]0YGJ(LK$QU/KNL:='%;'& T\NLJ5T?A(
M$/.GS+!65/,I5%,?SK+1SUD06;C4@)W(45F'DP68:$@;H&)E:&$!MJ:@J94:
M%2U T'&6 ;5)"D.F&*E1406_($;'"C10BHUZ$I!-E8I>AMH=HGIGJ 3^+% Y
M<:'.=K1D'5\T%XBICZ(93&(A@1N9]4>XKO4G3S>\U@PD-:M52MJ(E3JMMRZB
MC^_@7P161[P4HZ!S,17*:$AD4;Q<._[EIU]]S"0,?+A(*H95^2'N&V)*])7/
MCG#/^OGLQ#\LC,W:(&D866G=.QGU378Y_R4I*L>_O/_XKDY]&&(D:'!=XD,K
MS:%C1395X=-S1]9>T1L'_ Z;*]'\Y[N]B7'O/M[_Y:C_T\G1_J_]_9_/CDYV
M ,\OX=AW;6AK![T9JAE[ DV,0;V-L6XTT."R/V_1_\%],CH?@]A(XW[SI[E3
M>7W8?2H<,?_$,SG[</!6I^>M9)$%<.AD*'=._G 8:-&QO955X/ V0N,4C&RR
M5)W.M5PBX[1+>9E/'N@TIYLJF9<-E,PVIU5]2>O:)P!TF->-=3@3.S0S7E<
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M+PD!$/^M*58G"">-B@7<@C1TE7\"48G&FI[?*FW82D,&E%K7F36C 3MDHA;
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MLRILG,"$*DM!9]J[T;QLE%AH*AVM'7@7JIB?-0H/Q'SJ.G\:W6]9H7T$!2[
MVA)X#WJQ#3OXLKKU#VT&KYHJ Z?7(_,0 !];%^(0<"+%( PPCZ'S\R$LW71O
M#(=RW+WGE^.#"ST7FEFTO!O2W$%^JK*Q7K=<^TLK$7$NP(@U(I83'&33G%L'
M'MLCKSD!GX8R3&+T_,#D*1D+R *WYG+[$&VQ(CZ=HXPA8#:#' JN&&XY7UU
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M3",/*BZN E9>SN8-"+H[M,.\1XMX/C#CTXPTLT;WN\(:9)0V<9/55ONM,"A
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M   1              "  0    !D>6%I+3(P,C$P.#$P+GAS9%!+ 0(4 Q0
M   (  %$"U-2!?6 V 0  .8L   5              "  9X#  !D>6%I+3(P
M,C$P.#$P7V1E9BYX;6Q02P$"% ,4    "  !1 M30G579O<%  !$/   %0
M            @ &I"   9'EA:2TR,#(Q,#@Q,%]L86(N>&UL4$L! A0#%
M  @  40+4P)F*]QT!   ?BT  !4              ( !TPX  &1Y86DM,C R
M,3 X,3!?<')E+GAM;%!+ 0(4 Q0    (  %$"U/F(^2LYA0  &-^   3
M          "  7H3  !D>6%I,C R,3 X,#E?.&LN:'1M4$L! A0#%     @
M 40+4[:(*CFB%@  _U@   T              ( !D2@  &5X7S(W,SDP,BYH
M=&U02P$"% ,4    "  !1 M3B"*/L2$I   R$0$ #0              @ %>
F/P  97A?,C<T,S$X+FAT;5!+!08     !P ' +\!  "J:      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
